Cellectis (CLLS) Free Cash Flow Growth (3y) (2018 - 2026)
Cellectis (CLLS) Free Cash Flow Growth (3y) (2018 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
24.91% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
20.11% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
14.71% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Cellectis |
17.40 Bn |
17.21 Bn |
- |
18.63% |
| Date | Value |
|---|
| Mar 31, 2026 |
18.63% |
| Dec 31, 2025 |
-29.47% |
| Sep 30, 2025 |
75.21% |
| Jun 30, 2025 |
23.85% |
| Mar 31, 2025 |
22.48% |
| Dec 31, 2024 |
56.81% |
| Sep 30, 2024 |
41.94% |
| Jun 30, 2024 |
115.25% |
| Mar 31, 2024 |
10.98% |
| Dec 31, 2023 |
33.90% |
| Sep 30, 2023 |
4.51% |
| Jun 30, 2023 |
-31.56% |
| Mar 31, 2023 |
-71.00% |
| Dec 31, 2022 |
39.97% |
| Sep 30, 2022 |
-14.21% |
| Jun 30, 2022 |
-7.54% |
| Mar 31, 2022 |
-20.46% |
| Dec 31, 2021 |
-27.79% |
| Sep 30, 2021 |
-23.27% |
| Jun 30, 2021 |
17.74% |
